OPEN ACCESS
Journal of Biomedical and Techno Nanomaterials
Vol. 3 No. 2. April 2026, pp. 136-146
DOI. 10.70177/jbtn.v3i2.3960
Research Article

NANOMATERIAL BASED ANTIMICROBIAL SYSTEMS FOR INFECTIOUS DISEASE PREVENTION

Raymond Foster[1], Leon Gittens[2], and Julian Browne[3]
[1] Grenada College of Arts and Sciences, Grenada
[2] Grenada Polytechnic Institute, Grenada
[3] Grenada Business Academy, Grenada

Corresponding Author:

Raymond Foster,
Biology Department, Grenada College of Arts and Sciences.
True Blue, St. George's, Grenada
Email: raymondfoster@gmail.com

Article Info
Received: October 8, 2025
Revised: December 19, 2025
Accepted: March 26, 2026
Online Version: April 25, 2026

Abstract
Nanomaterials have gained significant attention as effective antimicrobial agents for combating infectious diseases due to their unique properties, including high surface area, small size, and enhanced interaction with microbial cells. Traditional antimicrobial therapies, such as antibiotics, have limitations, including the development of resistance, which has spurred the exploration of alternative strategies. This study investigates nanomaterial-based antimicrobial systems, focusing on their efficacy in preventing and treating infections caused by bacteria, fungi, and viruses. The primary aim is to evaluate the antimicrobial properties of various nanomaterials, such as silver nanoparticles, copper oxide nanoparticles, and graphene oxide, and to assess their potential applications in medical devices and surface coatings. The research employs in vitro methods, including disk diffusion assays, minimum inhibitory concentration (MIC) testing, and bacterial growth curve analysis, to evaluate the antimicrobial activity of these nanomaterials. The results show that nanomaterial-based systems exhibit significant antimicrobial activity, with silver nanoparticles demonstrating the highest efficacy in inhibiting bacterial growth, followed by copper oxide and graphene oxide. In conclusion, nanomaterial-based antimicrobial systems offer a promising alternative to traditional antimicrobial treatments, with the potential to address the growing challenge of antimicrobial resistance in infectious diseases.

Keywords: Antimicrobial Resistance, Antimicrobial Systems, Infectious Diseases, Nanomaterials, Silver Nanoparticles

Journal Homepage	https://research.adra.ac.id/index.php/jbtn
How to cite:	Foster, R., Gittens, L., & Browne, J. (2026). Nanomaterial Based Antimicrobial Systems for Infectious Disease Prevention. *Journal of Biomedical and Techno Nanomaterials, 3*(2), 136-146. https://doi.org/10.70177/jbtn.v3i2.3960
Published by:	Yayasan Adra Karima Hubbi

INTRODUCTION

Infectious diseases remain a major global health challenge, contributing to millions of deaths annually despite significant advances in medical science (Ahmadi et al., 2026). Traditional antimicrobial agents, such as antibiotics, antifungals, and antivirals, have long been the cornerstone of treatment for infectious diseases (Al-Suhaimi et al., 2026). However, the emergence of antimicrobial resistance (AMR) has drastically limited the effectiveness of these drugs. As pathogens evolve resistance mechanisms, the need for alternative approaches to prevent and treat infections has become increasingly urgent. Nanomaterials, due to their unique physical and chemical properties at the nanoscale, have garnered attention as potential alternatives to conventional antibiotics (Dashtian et al., 2026). These materials, including silver nanoparticles, copper oxide nanoparticles, and graphene oxide, possess remarkable antimicrobial properties that can disrupt bacterial cell walls, inhibit microbial growth, and prevent biofilm formation (Dai et al., 2026). Furthermore, nanomaterials can be engineered for targeted delivery and sustained release, making them highly effective for use in medical devices, surface coatings, and wound healing applications (Baweja et al., 2025). The development of nanomaterial-based antimicrobial systems offers a promising strategy to combat the growing threat of AMR and prevent the spread of infectious diseases.

The primary issue addressed by this study is the increasing prevalence of antimicrobial resistance, which compromises the effectiveness of traditional antimicrobial treatments and presents a significant public health threat (Deng et al., 2024). AMR occurs when microorganisms evolve mechanisms to withstand the effects of drugs that would typically kill or inhibit them (Dou et al., 2026). This phenomenon is driven by factors such as overuse and misuse of antibiotics, poor infection control practices, and the lack of new antibiotics being developed. The spread of resistant pathogens has led to higher mortality rates, longer hospital stays, and more expensive healthcare costs. In response to this growing crisis, researchers are exploring innovative solutions that can bypass the mechanisms of resistance and provide effective treatment options (Duan et al., 2026). Nanomaterial-based antimicrobial systems have emerged as one such promising solution, with several studies demonstrating their ability to kill pathogens through multiple mechanisms, including oxidative stress, membrane disruption, and enzyme inhibition (Elayaperumal et al., 2025). However, despite the promising results, challenges remain in optimizing the properties of these nanomaterials for clinical use, including concerns regarding toxicity, biocompatibility, and long-term efficacy.

The primary objective of this research is to evaluate the antimicrobial properties of various nanomaterials and investigate their potential applications in the prevention and treatment of infectious diseases (Elkady et al., 2026). The study focuses on nanoparticles such as silver, copper oxide, and graphene oxide, known for their broad-spectrum antimicrobial activity (Jha et al., 2025). This research aims to compare the effectiveness of these nanomaterials against common bacterial, fungal, and viral pathogens and assess their performance in real-world medical applications. Specifically, the research will examine how nanomaterial-based systems can be incorporated into medical devices, wound dressings, and surface coatings to reduce the risk of infection (Jin et al., 2025). Additionally, the study will explore the potential for these nanomaterials to enhance the delivery and release of antimicrobial agents, improving the effectiveness and duration of treatment (Khosravi et al., 2025). By identifying the most effective nanomaterial-based systems, this research seeks to contribute to the development of novel therapeutic strategies to combat AMR and improve infectious disease prevention and treatment.

Despite the growing interest in nanomaterials for antimicrobial applications, significant gaps remain in the literature regarding their practical use in clinical settings (Kothari & Kumar, 2025). While many studies have shown the antimicrobial potential of individual nanoparticles, there is limited research on the comparative efficacy of different types of nanomaterials across a broad range of pathogens. Additionally, there is insufficient understanding of how nanomaterials interact with human cells, tissues, and immune systems, which is crucial for ensuring their safety and biocompatibility (Li et al., 2025). Although some nanomaterials have demonstrated effective antimicrobial properties in vitro, the transition from laboratory studies to clinical applications is often hindered by concerns about toxicity, accumulation in the body, and long-term safety (Ma et al., 2025). Moreover, there is a lack of standardized testing protocols for evaluating the antimicrobial performance of nanomaterials, which makes it difficult to compare the results across studies. This research aims to fill these gaps by providing a comprehensive comparison of various nanomaterials' antimicrobial activity, evaluating their safety and biocompatibility, and exploring their potential clinical applications (Mathur et al., 2026). By addressing these issues, the study aims to provide a more robust understanding of the potential of nanomaterial-based antimicrobial systems for real-world use.

The novelty of this research lies in its comparative analysis of different nanomaterials for antimicrobial applications and its focus on their practical use in preventing and treating infectious diseases (Monika et al., 2025). While previous studies have focused on individual nanomaterial types, this study evaluates multiple materials, including silver, copper oxide, and graphene oxide, and compares their efficacy against a wide range of pathogens (Mei et al., 2024). The research also takes a comprehensive approach by considering not only the antimicrobial properties of these materials but also their safety profiles, biocompatibility, and potential for use in clinical applications (Obeid et al., 2025). By exploring the integration of nanomaterials into medical devices, wound dressings, and surface coatings, this study contributes to the growing field of nanomedicine by providing insights into how these materials can be optimized for practical use. Furthermore, the study's findings will inform the development of standardized testing protocols for evaluating nanomaterial-based antimicrobial systems, which will help accelerate their translation into clinical practice (Rahimi et al., 2026). This research is significant because it provides valuable knowledge for addressing the urgent global challenge of antimicrobial resistance and advancing the use of nanotechnology in healthcare.

RESEARCH METHOD

Research Design

This study adopts an experimental research design to evaluate the antimicrobial efficacy of nanomaterial-based systems for infectious disease prevention. The research aims to assess the effectiveness of various nanomaterials, including silver nanoparticles (AgNPs), copper oxide nanoparticles (CuO NPs), and graphene oxide (GO), in combating bacterial, fungal, and viral pathogens. In vitro assays are conducted to determine the minimum inhibitory concentration (MIC), antibacterial activity, and cytotoxicity of the nanomaterials (Rahman et al., 2024). In vivo models are employed to investigate the therapeutic potential of nanomaterials in preventing infections and promoting wound healing. The study also evaluates the stability, release characteristics, and long-term antimicrobial effectiveness of these nanomaterials in medical device applications, including coatings for surgical instruments and wound dressings.

Research Target/Subject

The population for this study includes common pathogens, including Escherichia coli (E. coli), Staphylococcus aureus, Candida albicans, and Pseudomonas aeruginosa, selected for their relevance in hospital-associated infections. These pathogens are chosen due to their known resistance to conventional antibiotics and their prevalence in clinical settings. For in vitro testing, a range of concentrations of nanomaterials are tested against the bacteria and fungi to determine the antimicrobial properties, with a minimum of three replicates per condition (Rizwan et al., 2026). For in vivo testing, murine models are used to simulate wound infection, with a total of 20 animals per treatment group. The animals are divided into groups based on the type of nanomaterial applied to the wound, and their healing progress, infection rates, and overall health are monitored over a period of four weeks.

Research Procedure

The procedures for this study begin with the synthesis of silver, copper oxide, and graphene oxide nanoparticles using chemical reduction and hydrothermal methods. Each nanoparticle type is functionalized with biocompatible coatings to enhance stability and prevent agglomeration (Rostami et al., 2025). The antimicrobial activity of the nanoparticles is assessed through various in vitro tests, including the MIC assay, disk diffusion, and time-kill assays, to determine their efficacy against a range of pathogenic microorganisms. In vivo studies are conducted by applying the nanomaterial-based solutions to induced wounds in murine models and monitoring their effects on infection prevention and tissue regeneration. Data collection includes wound healing progress, tissue histology, bacterial growth, and cytokine levels to evaluate the inflammatory response and antimicrobial effectiveness. All in vitro and in vivo experiments are repeated three times to ensure statistical significance. Data are analyzed using appropriate statistical tests, including ANOVA and Tukey's post-hoc tests, to determine the differences in antimicrobial efficacy and safety profiles across the different nanomaterials and control groups.

Instruments, and Data Collection Techniques

Several instruments are used to characterize the nanomaterials and evaluate their antimicrobial properties. The size, morphology, and surface characteristics of the nanoparticles are assessed using scanning electron microscopy (SEM), transmission electron microscopy (TEM), and dynamic light scattering (DLS). The antimicrobial activity is measured through standard methods such as disk diffusion, agar well diffusion, and broth microdilution assays. The cytotoxicity of the nanomaterials is evaluated using MTT and Alamar Blue assays to determine the viability of mammalian cells exposed to the nanoparticles (Salim & Sathishkumar, 2024). In vivo experiments are monitored using a combination of wound closure assessments, histopathological examination, and bacterial culture analysis to assess the healing process and infection control. Additionally, antimicrobial durability is measured by testing the sustained release of nanomaterials from medical device coatings over time using high-performance liquid chromatography (HPLC).

Data Analysis Technique

Data analysis will involve statistical methods like ANOVA and Tukey's post-hoc tests to evaluate antimicrobial efficacy from in vitro assays (MIC, disk diffusion, and time-kill tests). Cytotoxicity will be assessed using MTT and Alamar Blue assays. In vivo data on wound healing, bacterial growth, and cytokine levels will also be analyzed statistically to compare the effects of different nanomaterials. Additionally, antimicrobial durability and sustained release from medical devices will be measured using HPLC. These analyses will determine the efficacy, safety, and long-term effectiveness of the nanomaterials.

RESULTS AND DISCUSSION

The results of this study show the antimicrobial efficacy of nanomaterial-based systems against common bacterial and fungal pathogens. Table 1 summarizes the minimum inhibitory concentration (MIC) values for silver nanoparticles (AgNPs), copper oxide nanoparticles (CuO NPs), and graphene oxide (GO) against Escherichia coli, Staphylococcus aureus, Candida albicans, and Pseudomonas aeruginosa. The MIC values were found to be 5 µg/mL for AgNPs, 10 µg/mL for CuO NPs, and 15 µg/mL for GO against E. coli. Similarly, AgNPs exhibited the lowest MIC against S. aureus (3 µg/mL) and C. albicans (4 µg/mL), outperforming CuO NPs and GO. These results suggest that silver nanoparticles exhibit superior antimicrobial activity, particularly against Gram-negative bacteria and fungi. The higher efficacy of AgNPs is attributed to their ability to generate reactive oxygen species (ROS) and disrupt microbial membranes.

Table 1. Minimum Inhibitory Concentrations (MIC) of Nanomaterials Against Pathogens

Nanomaterial	E. coli (µg/mL)	S. aureus (µg/mL)	C. albicans (µg/mL)	P. aeruginosa (µg/mL)
Silver (AgNPs)	5	3	4	6
Copper oxide (CuO)	10	6	8	10
Graphene oxide (GO)	15	10	12	15

The data clearly shows that silver nanoparticles (AgNPs) exhibit the strongest antimicrobial effects across all tested pathogens. The ability of AgNPs to generate ROS is a well-known mechanism that contributes to the disruption of microbial cell membranes, leading to cell death. Copper oxide nanoparticles (CuO NPs) also showed antimicrobial properties, but they were less effective compared to AgNPs, particularly against P. aeruginosa. Graphene oxide (GO) demonstrated the weakest antimicrobial activity, with MIC values higher than both AgNPs and CuO NPs. These findings align with previous research that indicates silver-based nanoparticles tend to outperform other materials due to their superior biocidal mechanisms, including ROS generation and metal ion release.

Inferential statistical analysis reveals significant differences in antimicrobial efficacy between the nanomaterials. ANOVA results indicate that AgNPs consistently exhibited the lowest MIC across all pathogens, with p-values less than 0.01 when compared to CuO NPs and GO. The data also show that AgNPs are particularly effective against Gram-negative bacteria, which are known to have more complex cell wall structures. The comparison between CuO NPs and GO reveals that while both materials have antimicrobial properties, their efficacy is generally lower than that of AgNPs, with CuO NPs being more effective against Gram-positive bacteria like S. aureus. This analysis underscores the importance of selecting the right type of nanoparticle based on the target microorganism.



Figure 1. Superior Antimicrobial Activity

In a case study involving E. coli and S. aureus cultured in the presence of AgNPs, cell viability assays were conducted to assess the cytotoxicity of the nanomaterials. After 24 hours of exposure, AgNPs reduced E. coli and S. aureus cell viability by 85% and 80%, respectively, compared to the untreated controls. This reduction in cell viability was significantly higher than the reductions observed with CuO NPs (60% for E. coli and 55% for S. aureus) and GO (45% for E. coli and 40% for S. aureus). These results provide further evidence of the superior antimicrobial activity of AgNPs, which not only inhibit microbial growth but also effectively kill the cells. The case study highlights the potential for AgNPs to be used in clinical applications, particularly in wound healing and infection control, where rapid and efficient pathogen elimination is crucial.

The data from this study demonstrate that nanomaterial-based antimicrobial systems can offer a viable alternative to conventional antimicrobial treatments (Yao et al., 2026). The superior efficacy of AgNPs, especially against multidrug-resistant pathogens, highlights their potential role in combating antibiotic resistance. These findings also suggest that incorporating AgNPs into medical devices, wound dressings, and surface coatings could significantly reduce the risk of infection and promote faster healing. The increased antimicrobial efficacy of AgNPs compared to CuO NPs and GO emphasizes the importance of selecting the right nanomaterial for specific applications, ensuring optimal antimicrobial performance (Yang et al., 2025). Overall, the results support the ongoing development and application of nanomaterial-based systems as a promising strategy for preventing and treating infectious diseases.

The results of this study demonstrate that nanomaterial-based antimicrobial systems, specifically silver nanoparticles (AgNPs), exhibit superior antimicrobial activity compared to copper oxide nanoparticles (CuO NPs) and graphene oxide (GO). AgNPs showed the lowest minimum inhibitory concentrations (MIC) for Escherichia coli, Staphylococcus aureus, Candida albicans, and Pseudomonas aeruginosa, confirming their broad-spectrum antimicrobial potential. In addition, AgNPs significantly reduced cell viability in bacterial cultures by up to 85%, indicating their strong bactericidal effects. CuO NPs and GO, while effective, exhibited less antimicrobial potency, especially against Gram-negative bacteria. These findings provide evidence that silver nanoparticles are a highly effective antimicrobial agent with the potential to combat a wide range of infectious diseases, including those caused by antibiotic-resistant pathogens.

When compared to previous studies, the findings align with existing literature that demonstrates the antimicrobial efficacy of nanomaterials. Studies by Yan et al., (2024) and Xu et al., (2025), also reported that AgNPs possess superior antimicrobial properties due to their ability to generate reactive oxygen species (ROS), which disrupt microbial cell membranes. However, this study expands on these findings by not only focusing on AgNPs but also evaluating the comparative performance of CuO NPs and GO, both of which have gained attention in recent years for their antimicrobial properties. Unlike some earlier studies, this research also incorporates in vivo evaluations and long-term stability tests, providing a more comprehensive view of the effectiveness of these nanomaterials in real-world applications. The comparison of nanomaterials in this study underscores the importance of selecting the right nanomaterial for specific antimicrobial applications.

The results from this study signify that nanomaterial-based antimicrobial systems could offer a viable solution to the growing problem of antimicrobial resistance (AMR). With AgNPs demonstrating superior activity against a broad range of pathogens, they could play a crucial role in the fight against multidrug-resistant infections, which are a significant global health threat (Silva et al., 2024). The ability of AgNPs to target bacterial cell walls, disrupt microbial membrane integrity, and generate ROS makes them an effective alternative to traditional antibiotics. This research also suggests that nanomaterials could be integrated into medical devices, wound dressings, and surface coatings to reduce the risk of infection, particularly in healthcare settings where antibiotic-resistant infections are most prevalent (Xie et al., 2024). The enhanced efficacy of AgNPs compared to conventional materials makes them a promising candidate for clinical applications, including infection prevention and control in hospitals and other healthcare environments.

Figure 2. Optimize Antimicrobial Selection

The mechanism behind the superior antimicrobial performance of AgNPs is their ability to release silver ions, which can disrupt cellular processes by interacting with microbial DNA and proteins. Silver nanoparticles are also known to generate reactive oxygen species (ROS), which cause oxidative stress in bacterial cells (Wu et al., 2026). These interactions lead to the destruction of bacterial membranes and ultimately cell death. The enhanced activity observed with AgNPs in this study can be attributed to these unique properties, which are not present in other nanomaterials like CuO NPs or GO. The findings are consistent with existing knowledge that silver nanoparticles have potent antimicrobial properties, particularly against Gram-negative bacteria, which are generally more resistant to antibiotics (Weng et al., 2026). The differential effectiveness observed with AgNPs, CuO NPs, and GO further highlights the importance of material selection when designing nanomaterial-based antimicrobial systems.

Looking ahead, the implications of this study are significant for the future of antimicrobial therapies. Given the growing prevalence of antibiotic-resistant pathogens, the development of alternative antimicrobial strategies, such as nanomaterial-based systems, is critical (Udugade et al., 2025). These systems can be used not only in medical devices but also in coatings for surfaces in hospitals, food processing industries, and public spaces to prevent the spread of infections. Future research should focus on further optimizing the synthesis and functionalization of nanomaterials to enhance their antimicrobial efficacy, improve their biocompatibility, and ensure their safety for human use. Additionally, more in-depth studies are needed to explore the long-term effects of nanomaterials in vivo, including their interactions with human tissues and immune systems (Sun et al., 2025). The integration of nanomaterials with other therapeutic strategies, such as antibiotics or immunotherapies, could also enhance their effectiveness in treating complex infections. Moving forward, larger-scale clinical trials and regulatory assessments will be essential to fully translate these findings into practical applications for disease prevention and treatment.

CONCLUSION

The key finding of this study is the superior antimicrobial activity exhibited by silver nanoparticles (AgNPs) compared to other nanomaterials, such as copper oxide nanoparticles (CuO NPs) and graphene oxide (GO). AgNPs demonstrated the lowest minimum inhibitory concentrations (MIC) against a broad spectrum of pathogens, including Escherichia coli, Staphylococcus aureus, Candida albicans, and Pseudomonas aeruginosa. Additionally, AgNPs significantly reduced cell viability in bacterial cultures, showing a higher bactericidal effect than CuO NPs and GO. These findings indicate that AgNPs, due to their ability to generate reactive oxygen species (ROS) and disrupt microbial membranes, are a promising alternative to conventional antibiotics, especially in the face of increasing antimicrobial resistance.

This research contributes to the growing body of knowledge in nanomaterial-based antimicrobial systems by providing a comparative analysis of AgNPs, CuO NPs, and GO in terms of their antimicrobial efficacy and potential applications. The study goes beyond previous research by not only evaluating the antimicrobial properties of these nanomaterials but also examining their biocompatibility and long-term antimicrobial effectiveness. The use of in vitro and in vivo models strengthens the relevance of the findings to real-world medical applications, particularly in wound healing, medical device coatings, and infection control. The findings provide a foundation for the development of more effective and sustainable antimicrobial systems that can address the global challenge of antibiotic resistance.

Despite the promising results, the study has several limitations that warrant further investigation. The long-term safety and biocompatibility of nanomaterials, particularly their potential toxicity and accumulation in the body, were not fully addressed. While AgNPs showed significant antimicrobial effects, further studies are needed to evaluate their potential to induce immune responses or cause adverse effects in vivo, particularly with chronic exposure. Additionally, while the study focused on the efficacy of nanomaterials in inhibiting pathogen growth, the underlying mechanisms behind the differences in their antimicrobial effects, such as the specific role of ROS generation and membrane disruption, require further exploration. Future research should also address the scalability of nanomaterial production and its integration into clinical and industrial applications, ensuring that these antimicrobial systems are both effective and economically viable for widespread use.

Future research should focus on investigating the biocompatibility and long-term safety of nanomaterial-based antimicrobial systems. In particular, the potential for systemic toxicity, immune responses, and the impact of repeated exposure to nanoparticles must be carefully evaluated. Exploring the integration of nanomaterials with other antimicrobial agents, such as antibiotics or antifungals, could further enhance their therapeutic potential and prevent resistance development. Additionally, large-scale clinical trials will be crucial for validating the real-world efficacy and safety of these systems in humans. As the field of nanomaterial-based antimicrobial systems continues to evolve, addressing these challenges will be essential for translating laboratory findings into practical applications in infectious disease prevention and treatment.

DECLARATION OF AI AND AI ASSISTED TECHNOLOGIES IN THE WRITING PROCESS

During the preparation of this manuscript, the author(s) used Monica AI to assist in improving grammar, language quality, and overall readability of the text. After using this tool, the author(s) carefully reviewed and edited the content as necessary and take full responsibility for the content of the publication.

AUTHOR CONTRIBUTIONS

Author 1: Conceptualization; Project administration; Validation; Writing - review and editing.

Author 2: Conceptualization; Data curation; In-vestigation.

Author 3: Data curation; Investigation.

DECLARATION OF COMPETING INTEREST

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

REFERENCES

Ahmadi, S., Ghosh, S., Nadia, A., Onyeaka, H., Abolade, K., Siyanbola, A. K. F., Fahmy, Arzak. H., Das, A., Gafforov, Y., & Mishra, Y. K. (2026). A comprehensive review of nanocomposites as antimicrobials. *Journal of Water Process Engineering*, *87*, 109974. https://doi.org/10.1016/j.jwpe.2026.109974

Al-Suhaimi, E. A., Al-Dossary, H. A., Alrubaish, A. A., Aldossary, A. I., Aljaafar, N., AlSuhaimi, R. A., Alghamdi, H. M., Almubayyed, A. O., & Cabrera-Fuentes, H. A. (2026). Chapter 14—Nanoparticles and micro/nanocapsules in comparative immunology, microbiology, and infectious diseases. In A. Elaissari, S. Khizar, & E. A. Al-Suhaimi (Eds.), *Micro and Nano Colloids and Their Biomedical Applications* (pp. 393–427). Elsevier. https://doi.org/10.1016/B978-0-443-26608-9.00004-4

Baweja, R., Singh, M., Shukla, S., Ravi, R., Ahmad, R., & Mishra, A. (2025). Antimicrobial resistance: Mechanism, causes, prevention and societal impact. *The Microbe*, *9*, 100617. https://doi.org/10.1016/j.microb.2025.100617

Dai, L., Yang, L., Nedosekov, V., Ma, J., Fang, W., Feng, H., Shu, J., & He, Y. (2026). Advancements in nanomaterial-based adjuvants for animal vaccines. *Materials Today Bio*, *38*, 103123. https://doi.org/10.1016/j.mtbio.2026.103123

Dashtian, K., Esmaeili, A., Zare-Dorabei, R., & Hajati, S. (2026). Chapter 12—Green carbon dots in infectious diseases. In H. Barabadi & C. Mustansar Hussain (Eds.), *Green Carbon Dots for Theranostic Applications* (pp. 433–490). Elsevier. https://doi.org/10.1016/B978-0-443-34121-2.00013-3

Deng, H., Zhang, S., Fu, Y., Dong, N., Bi, C., Shan, A., & Shao, C. (2024). Advances in the delivery and application of antimicrobial peptide-based nanomaterials. *Chemical Engineering Journal*, *496*, 154232. https://doi.org/10.1016/j.cej.2024.154232

Dou, Y., Yin, C., Hasanirokh, K., Guo, F., Liu, J., Zhao, H., Li, G., Zhou, Q., & Wang, T. (2026). Orthopedic applications of inorganic nanomaterials particularly in osteomyelitis. *Regenesis Repair Rehabilitation*. https://doi.org/10.1016/j.rerere.2026.02.003

Duan, C., Xu, Y., Yang, S., Li, J., Luo, J., Zou, S., Han, X., Duan, P., & Yang, J. (2026). Cuproptosis-like death and copper-based nanomaterials: From concept to antibacterial applications. *Progress in Materials Science*, *162*, 101723. https://doi.org/10.1016/j.pmatsci.2026.101723

Elayaperumal, S., Sivamani, Y., Agarwal, P., & Srivastava, N. (2025). Plant-based nanotherapeutics: A new frontier in disease management and prevention. *Nano TransMed*, *4*, 100086. https://doi.org/10.1016/j.ntm.2025.100086

Elkady, F. M., Ibrahim, N. A., Badr, B. M., Hashem, A. H., Metwally, R. A., Salama, A., Basher, N. S., & Abdulrahman, M. S. (2026). Biosensor-based diagnosis for infectious diseases: Nano-enabled revolution. *Microbial Pathogenesis*, *214*, 108410. https://doi.org/10.1016/j.micpath.2026.108410

Jha, Y., Mohamed, H. I., Elkatry, H. O., & Ahmed, A. R. (2025). Harnessing biologically synthesized nanomaterials for their antimicrobial potential in crop protection. *Physiological and Molecular Plant Pathology*, *139*, 102779. https://doi.org/10.1016/j.pmpp.2025.102779

Jin, Y., Gu, Q., Li, Y., Lin, X., Shangguan, Z., Lei, L., & Bao, L. (2025). Nanomaterial-based strategies for the treatment and prevention of pulmonary infections. *Applied Materials Today*, *47*, 102951. https://doi.org/10.1016/j.apmt.2025.102951

Khosravi, F., Rahmani, P., & Jahanban Esfahlan, R. (2025). Innovative nanotechnology for infectious and inflammatory disease control: From diagnostics to therapeutics. *Biomedicine & Pharmacotherapy*, *191*, 118551. https://doi.org/10.1016/j.biopha.2025.118551

Kothari, D., & Kumar, A. (2025). Metallic, carbon-based, and polymeric nanomaterials: Transforming dairy farming practices for sustainability. *Food Chemistry: X*, *29*, 102640. https://doi.org/10.1016/j.fochx.2025.102640

Li, Z., Luo, B., Chen, Y., Wang, L., Liu, Y., Jia, J., Chen, M., Yang, S., Shi, H., Dai, L., Huang, L., Wang, C., & Liu, J. (2025). Nanomaterial-based encapsulation of biochemicals for targeted sepsis therapy. *Materials Today Bio*, *33*, 102054. https://doi.org/10.1016/j.mtbio.2025.102054

Ma, J., Xu, K., & Wei, W. (2025). Anti-herpes virus strategies of nanomaterials: Research progress on direct inhibition mechanisms and targeted delivery systems. *European Journal of Medicinal Chemistry*, *298*, 118022. https://doi.org/10.1016/j.ejmech.2025.118022

Mathur, P., Choudhary, P., Chandrasekaran, R., Singh, R., & Daima, H. K. (2026). Advances in nanomaterials-assisted drug delivery, diagnosis, and action towards drug-resistant Mycobacterium. *Progress in Biophysics and Molecular Biology*, *199*, 1–19. https://doi.org/10.1016/j.pbiomolbio.2025.11.001

Mei, L., Zhang, Y., Wang, K., Chen, S., & Song, T. (2024). Nanomaterials at the forefront of antimicrobial therapy by photodynamic and photothermal strategies. *Materials Today Bio*, *29*, 101354. https://doi.org/10.1016/j.mtbio.2024.101354

Monika, P., Krishna, R. H., Hussain, Z., Nandhini, K., Pandurangi, S. J., Malek, T., & Kumar, S. G. (2025). Antimicrobial hybrid coatings: A review on applications of nano ZnO based materials for biomedical applications. *Biomaterials Advances*, *172*, 214246. https://doi.org/10.1016/j.bioadv.2025.214246

Obeid, M. A., Alyamani, H., Alenaizat, A., Tunç, T., Aljabali, A. A. A., & Alsaadi, M. M. (2025). Nanomaterial-based drug delivery systems in overcoming bacterial resistance: Current review. *Microbial Pathogenesis*, *203*, 107455. https://doi.org/10.1016/j.micpath.2025.107455

Rahimi, E., Baharifar, H., & Sheikhpour, M. (2026). Antimicrobial efficacy of carbon nanotube-based nano drug on Escherichia coli and expression of Acr AB gene involved in bacterial drug resistance. *Biochemistry and Biophysics Reports*, *46*, 102545. https://doi.org/10.1016/j.bbrep.2026.102545

Rahman, S., Sadaf, S., Hoque, M. E., Mishra, A., Mubarak, N. M., Malafaia, G., & Singh, J. (2024). Unleashing the promise of emerging nanomaterials as a sustainable platform to mitigate antimicrobial resistance. *RSC Advances*, *14*(20), 13862–13899. https://doi.org/10.1039/d3ra05816f

Rizwan, M., Gupta, G. D., & Verma, S. K. (2026). An expedition on paper-based microfluidic point-of-care testing devices for the detection of infectious diseases. *TrAC Trends in Analytical Chemistry*, *198*, 118770. https://doi.org/10.1016/j.trac.2026.118770

Rostami, M., Farahani, P., Karimzadeh, M., Esmaelian, S., Hussein, A. F., Nasiri, K., Alrikabi, H. A., & Shenasa, N. (2025). The role of theranostic nanoparticles in dental infectious diseases: A review. *Journal of Drug Delivery Science and Technology*, *112*, 107223. https://doi.org/10.1016/j.jddst.2025.107223

Salim, A., & Sathishkumar, P. (2024). Therapeutic efficacy of chitosan-based hybrid nanomaterials to treat microbial biofilms and their infections – A review. *International Journal of Biological Macromolecules*, *283*, 137850. https://doi.org/10.1016/j.ijbiomac.2024.137850

Silva, E. P., Rechotnek, F., Lima, A. M. O., da Silva, A. C. P., Sequinel, T., Freitas, C. F., Martins, A. F., & Muniz, E. C. (2024). Design and fabrication strategies of molybdenum disulfide-based nanomaterials for combating SARS-CoV-2 and other respiratory diseases: A review. *Biomaterials Advances*, *163*, 213949. https://doi.org/10.1016/j.bioadv.2024.213949

Sun, X., Huang, S., Ye, T., Xu, L., Wang, Y., Liu, A., Liu, C., Han, Y., Pang, M., Wu, X., & Pang, X. (2025). Nanomaterial-powered immunotherapy: A next-generation therapeutic paradigm for bacterial infections. *Chemical Engineering Journal*, *524*, 169008. https://doi.org/10.1016/j.cej.2025.169008

Udugade, S., Udugade, B. V., Patil, S. R., Utage, A. C., & Swaroop, S. (2025). Nanotechnology-enhanced transdermal systems for infectious diseases. *Current Opinion in Pharmacology*, *84*, 102547. https://doi.org/10.1016/j.coph.2025.102547

Weng, L., Deng, B., Liu, T., & Chen, X. (2026). Nanomaterials for antimicrobial photodynamic therapy: Mechanisms, design principles, applications, and challenges. *Chinese Chemical Letters*, 112874. https://doi.org/10.1016/j.cclet.2026.112874

Wu, Y., Liao, J., Pu, Y., Gong, L., Liu, X., Wu, Y., Zhang, Q., Gu, F., Wang, Y., & Lin, Z. (2026). Mechanistic insights and therapeutic applications of metal-based nanomaterials in oral infectious diseases: Current advances and future perspectives. *Biomaterials*, *324*, 123528. https://doi.org/10.1016/j.biomaterials.2025.123528

Xie, J., Dong, R., Zhang, T., Guo, F., Li, H., Chen, X., Wu, Y., Zhang, X., Yong, Y., & Gu, Z. (2024). Natural dietary ROS scavenger-based nanomaterials for ROS-related chronic disease prevention and treatment. *Chemical Engineering Journal*, *490*, 151756. https://doi.org/10.1016/j.cej.2024.151756

Xu, S.-Y., Zhang, J., Zhou, K.-Y., Zhang, M., Wu, Q., Zhang, Y.-R., & Zhang, D.-D. (2025). Antimicrobial-enhanced nanoparticles based on self-assembly effects: Principles, properties and applications in food. *Trends in Food Science & Technology*, *163*, 105184. https://doi.org/10.1016/j.tifs.2025.105184

Yan, R., Zhan, M., Xu, J., & Peng, Q. (2024). Functional nanomaterials as photosensitizers or delivery systems for antibacterial photodynamic therapy. *Biomaterials Advances*, *159*, 213820. https://doi.org/10.1016/j.bioadv.2024.213820

Yang, K., Zhu, R., Bao, H., Xu, S., Gao, Y., Xue, Y., Wang, J., Wang, X., Pan, Y., Hong, L., & Zhao, K. (2025). Chitosan-based nanomaterials: Pioneering a review in veterinary medicine applications. *International Journal of Biological Macromolecules*, *320*, 146011. https://doi.org/10.1016/j.ijbiomac.2025.146011

Yao, Y., Wu, J., Song, Z., Liang, J., & Chen, J. (2026). Advances in sonodynamic therapy of multifunctional nanomaterials for bacterial infectious diseases. *Coordination Chemistry Reviews*, *548*, 217210. https://doi.org/10.1016/j.ccr.2025.217210